S1900J: A Phase II Study of Amivantamab SC (subcutaneous) in Participants with MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNGMAP Sub-Study)

Title
A Phase II Study of Amivantamab SC (subcutaneous) in Participants with MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNGMAP Sub-Study)
Principal Investigator
Almubarak, Mohammed
Phase
II
Age Group
Adult
Applicable Disease Sites
Lung Cancer
Participating Institutions
Mary Babb Randolph Cancer Center
Contacts
Rachel Harper
Clinical Research Specialist
Phone: +1 304-293-6066
Email:

View on ClinicalTrials.gov